Literature DB >> 25361854

High and interrelated rates of PD-L1+CD14+ antigen-presenting cells and regulatory T cells mark the microenvironment of metastatic lymph nodes from patients with cervical cancer.

A Marijne Heeren1, Bas D Koster2, Sanne Samuels3, Debbie M Ferns4, Dafni Chondronasiou2, Gemma G Kenter5, Ekaterina S Jordanova4, Tanja D de Gruijl6.   

Abstract

A better understanding of the microenvironment in relation to lymph node metastasis is essential for the development of effective immunotherapeutic strategies against cervical cancer. In the present study, we investigated the microenvironment of tumor-draining lymph nodes of patients with cervical cancer by comprehensive flow cytometry-based phenotyping and enumeration of immune-cell subsets in tumor-negative (LN(-), n = 20) versus tumor-positive lymph nodes (LN(+), n = 8), and by the study of cytokine release profiles (n = 4 for both LN(-) and LN(+)). We found significantly lower CD4(+) and higher CD8(+) T-cell frequencies in LN(+) samples, accompanied by increased surface levels of activation markers (HLA-DR; ICOS; PD-1; CTLA-4) and the memory marker CD45RO. Furthermore, in LN(+), we found increased rates of a potentially regulatory antigen-presenting cell (APC) subset (CD11c(hi)CD14(+)PD-L1(+)) and of myeloid-derived suppressor cell subsets; the LN(+) APC subset correlated with significantly elevated frequencies of FoxP3(+) regulatory T cells (Treg). After in vitro stimulation with different Toll-like receptor (TLR) ligands (PGN; Poly-IC; R848), we observed higher production levels of IL6, IL10, and TNFα but lower levels of IFNγ in LN(+) samples. We conclude that, despite increased T-cell differentiation and activation, a switch to a profound immune-suppressive microenvironment in LN(+) of patients with cervical cancer will enable immune escape. Our data indicate that the CD14(+)PD-L1(+) APC/Treg axis is a particularly attractive and relevant therapeutic target to specifically tackle microenvironmental immune suppression and thus enhances the efficacy of immunotherapy in patients with metastasized cervical cancer. ©2014 American Association for Cancer Research.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 25361854     DOI: 10.1158/2326-6066.CIR-14-0149

Source DB:  PubMed          Journal:  Cancer Immunol Res        ISSN: 2326-6066            Impact factor:   11.151


  45 in total

Review 1.  Pharmacologic management of advanced cervical cancer: antiangiogenesis therapy and immunotherapeutic considerations.

Authors:  Teresa C Longoria; Krishnansu S Tewari
Journal:  Drugs       Date:  2015-11       Impact factor: 9.546

2.  PD-1 Blockade Expands Intratumoral Memory T Cells.

Authors:  Antoni Ribas; Daniel Sanghoon Shin; Jesse Zaretsky; Juliet Frederiksen; Andrew Cornish; Earl Avramis; Elizabeth Seja; Christine Kivork; Janet Siebert; Paula Kaplan-Lefko; Xiaoyan Wang; Bartosz Chmielowski; John A Glaspy; Paul C Tumeh; Thinle Chodon; Dana Pe'er; Begoña Comin-Anduix
Journal:  Cancer Immunol Res       Date:  2016-01-19       Impact factor: 11.151

Review 3.  Next generation immune-checkpoints for cancer therapy.

Authors:  Chiara Donini; Lorenzo D'Ambrosio; Giovanni Grignani; Massimo Aglietta; Dario Sangiolo
Journal:  J Thorac Dis       Date:  2018-05       Impact factor: 2.895

4.  Programmed death ligand 1 promotes lymph node metastasis and glucose metabolism in cervical cancer by activating integrin β4/SNAI1/SIRT3 signaling pathway.

Authors:  Shaojia Wang; Jiajia Li; Jie Xie; Fei Liu; Yachen Duan; Yong Wu; Shenglin Huang; Xianghuo He; Ziliang Wang; Xiaohua Wu
Journal:  Oncogene       Date:  2018-04-30       Impact factor: 9.867

5.  CD14+ macrophage-like cells as the linchpin of cervical cancer perpetrated immune suppression and early metastatic spread: A new therapeutic lead?

Authors:  A Marijne Heeren; Gemma G Kenter; Ekaterina S Jordanova; Tanja D de Gruijl
Journal:  Oncoimmunology       Date:  2015-05-07       Impact factor: 8.110

Review 6.  Leveraging immunotherapy for the treatment of gynecologic cancers in the era of precision medicine.

Authors:  Dmitriy Zamarin; Amir A Jazaeri
Journal:  Gynecol Oncol       Date:  2016-04       Impact factor: 5.482

7.  Identification of a prognostic immune signature for cervical cancer to predict survival and response to immune checkpoint inhibitors.

Authors:  Si Yang; Ying Wu; Yujiao Deng; Linghui Zhou; Pengtao Yang; Yi Zheng; Dai Zhang; Zhen Zhai; Na Li; Qian Hao; Dingli Song; Huafeng Kang; Zhijun Dai
Journal:  Oncoimmunology       Date:  2019-10-03       Impact factor: 8.110

Review 8.  Mechanisms of action of therapeutic antibodies for cancer.

Authors:  J M Redman; E M Hill; D AlDeghaither; L M Weiner
Journal:  Mol Immunol       Date:  2015-04-23       Impact factor: 4.407

9.  The distribution of cutaneous metastases correlates with local immunologic milieu.

Authors:  Joshua M Schulman; Mariela L Pauli; Isaac M Neuhaus; Roberto Sanchez Rodriguez; Keyon Taravati; Uk Sok Shin; Timothy H McCalmont; Michael D Rosenblum
Journal:  J Am Acad Dermatol       Date:  2016-01-09       Impact factor: 11.527

10.  Correlation of Circulating CD64+/CD163+ Monocyte Ratio and stroma/peri-tumoral CD163+ Monocyte Density with Human Papillomavirus Infected Cervical Lesion Severity.

Authors:  Piyawut Swangphon; Chamsai Pientong; Nuchsupha Sunthamala; Sureewan Bumrungthai; Miyuki Azuma; Pilaiwan Kleebkaow; Thumwadee Tangsiriwatthana; Ussanee Sangkomkamhang; Bunkerd Kongyingyoes; Tipaya Ekalaksananan
Journal:  Cancer Microenviron       Date:  2017-10-24
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.